Injectable Drug Delivery Market Size Forecast and Competitive Landscape Through 2031

The global injectable drug delivery market is witnessing significant growth, supported by the increasing prevalence of chronic diseases, rising demand for biologics, and technological advancements in drug administration systems. The injectable drug delivery market size is projected to reach US$ 84.08 billion by 2031 from US$ 48.89 billion in 2024. The market is expected to register a CAGR of 8.2% during 2025–2031. Increasing adoption of self-injection devices, growing use of monoclonal antibodies, and demand for patient-centric treatment solutions are contributing to the expansion of the global market.

The growing demand for effective and convenient drug administration is encouraging pharmaceutical companies and medical device manufacturers to develop innovative injectable delivery technologies. The Injectable Drug Delivery Market report by The Insight Partners provides comprehensive insights into market size, growth opportunities, key segments, regional developments, and the competitive landscape. It also examines the major factors influencing the market through 2031.

Download Sample PDF:
https://www.theinsightpartners.com/sample/TIPRE00004204

Injectable Drug Delivery Market Size and Growth Outlook

The injectable drug delivery market is expanding as injectable therapies become increasingly important for treating chronic diseases, acute medical conditions, and other healthcare requirements. Injectable administration allows medicines to enter the body through different routes, including intravenous, intramuscular, and subcutaneous injections. These methods are particularly important for treatments that require rapid action or high bioavailability.

The market's growth from US$ 48.89 billion in 2024 to US$ 84.08 billion by 2031 highlights the increasing importance of injectable drug delivery technologies across the pharmaceutical and healthcare industries. With an anticipated CAGR of 8.2% during 2025–2031, the market presents opportunities for manufacturers involved in injection devices, pharmaceutical formulations, packaging solutions, and advanced drug delivery systems.

The increasing use of biologics and biosimilars is another important factor supporting market expansion. Many biologics and monoclonal antibodies require parenteral administration because of their molecular complexity. Consequently, pharmaceutical companies are focusing on reliable and effective injectable delivery solutions to support different therapeutic applications.

Key Factors Driving the Injectable Drug Delivery Market

Rising Prevalence of Chronic Diseases

The increasing global burden of chronic diseases, particularly diabetes and cancer, is creating substantial demand for injectable therapies. Patients with diabetes require insulin administration, while oncology patients depend on injectable medicines for various treatment requirements.

The growing need for long-term treatment and effective medication administration is encouraging healthcare providers and pharmaceutical manufacturers to adopt advanced injectable drug delivery systems. This trend is expected to support the market's expansion throughout the forecast period.

Increasing Demand for Biologics and Monoclonal Antibodies

Biologics and monoclonal antibodies are becoming increasingly important in treating oncology, autoimmune disorders, and chronic inflammatory diseases. Their molecular complexity often requires parenteral administration, supporting demand for specialized injectable drug delivery devices and formulations.

The increasing development and use of these medicines are creating opportunities for manufacturers to introduce innovative delivery technologies that support effective and convenient drug administration.

Technological Advancements in Self-Injection Devices

Technological advancements in patient-centric injection systems are transforming the injectable drug delivery market. Autoinjectors and pen injectors are improving treatment convenience and supporting medication adherence.

These devices also facilitate home-based treatment, reducing the need for patients to depend entirely on healthcare facilities for medication administration. Continued innovation in self-injection technologies is expected to strengthen market growth.

Injectable Drug Delivery Market Segmentation Analysis

The injectable drug delivery market is segmented by device type, formulation, formulation packaging, therapeutic application, usability, route of administration, and end user.

By Device Type: The market includes conventional drug delivery devices and advanced drug delivery devices. Conventional drug delivery devices accounted for the largest share of 62.5% in 2024. Advanced devices include prefilled syringes, pen injectors, autoinjectors, needle-free injectors, and wearable injectors. Among advanced devices, wearable injectors are anticipated to register the fastest growth, with a CAGR of 14.3% during the forecast period.

By Formulation: The market includes conventional drug delivery, novel drug delivery, and long-acting injectable formulations. Conventional drug delivery accounted for the largest share of 53.7% in 2024. Reconstituted or lyophilized formulations are expected to witness the fastest growth within conventional drug delivery, registering a CAGR of 7.8%.

By Formulation Packaging: Packaging categories include ampoules, vials, cartridges, and bottles. Cartridges are anticipated to register the fastest growth, with a CAGR of 8.7%.

By Therapeutic Application: Key applications include diabetes, oncology, autoimmune disorders, cardiovascular diseases, infectious diseases, and pain management. Diabetes represented the largest therapeutic application segment, accounting for 31.7% of the market in 2024.

By Usability: The market is divided into disposable injectors and reusable injectors. Disposable injectors held the largest share of 65% in 2024.

By Route of Administration: Major routes include subcutaneous, intramuscular, and intravenous administration. The intravenous segment is anticipated to experience the fastest growth, registering a CAGR of 9.4%.

By End User: Pharmaceutical and biopharmaceutical companies, contract manufacturing organizations, and contract development and manufacturing organizations represent the major end users. The CMO and CDMO segment is expected to register the fastest growth, with a CAGR of 9.9%.

Regional Outlook of the Injectable Drug Delivery Market:

North America dominated the global injectable drug delivery market in 2024, accounting for 41.4% of the market share. The region benefits from developed healthcare infrastructure, high adoption of biologics, regulatory support, and widespread utilization of self-injection medications.

The United States injectable drug delivery market is projected to grow at a CAGR of 8.8% during the forecast period, supported by increasing demand for advanced pharmaceutical treatments and innovative drug administration technologies.

Europe represents another significant market, supported by the increasing prevalence of chronic diseases, growing biosimilar adoption, and reimbursement programs. The demand for cost-effective therapies and home-based injectable treatments is also contributing to regional market development.

Asia Pacific is anticipated to experience the fastest regional growth, registering a CAGR of 9.2% during the forecast period. Increasing patient populations, improved healthcare accessibility, growing biologics adoption, and expanding injectable drug manufacturing activities are supporting market expansion.

South and Central America, along with the Middle East and Africa, also present growth opportunities. Investments in healthcare infrastructure, increasing demand for affordable injectable medicines, and the growing burden of chronic and infectious diseases are supporting the development of these regional markets.

Top Key Players in the Injectable Drug Delivery Market

The competitive landscape includes established pharmaceutical packaging, medical device, and drug delivery technology companies. Major companies are focusing on product innovation, advanced injection systems, manufacturing capabilities, and strategic collaborations to strengthen their market positions.

The leading companies operating in the injectable drug delivery market include:

• B Braun SE
• Terumo Corporation
• Cardinal Health Inc.
• Phillips-Medisize
• Nipro Corporation
• Gerresheimer AG
• West Pharmaceutical Services Inc.
• Schott AG
• Becton Dickinson and Company
• Kindeva Drug Delivery LP

Other companies analyzed include Stevanato Group, SHL Medical AG, Owen Mumford Ltd., Haselmeier GmbH, Nemera, Vetter Pharma, AptarGroup Inc., Catalent Inc., and Bespak Europe Ltd.

Opportunities and Recent Developments

Long-acting injectable formulations represent an important opportunity for market participants. Long-acting injectable antiretrovirals can support HIV prevention and treatment adherence through less frequent dosing. Similarly, long-acting injectable antipsychotics can improve medication adherence and help reduce relapse and hospitalization rates.

Injectable immunotherapies are also creating opportunities in oncology. Subcutaneous checkpoint inhibitors and biosimilars are supporting the development of more accessible and convenient cancer treatment options.

Recent industry developments further demonstrate the growing focus on innovative injection technologies. In December 2025, Intas Pharmaceuticals entered into an exclusive agreement with IntegriMedical to introduce India's first needle-free injection system for IVF and gynecology treatments. In October 2025, West Pharmaceutical Services launched its West Synchrony Prefillable Syringe System at CPHI Worldwide in Frankfurt, Germany. These developments highlight the industry's focus on improving injection convenience, expanding treatment options, and advancing patient-centric drug delivery solutions.

Future Outlook:

The global injectable drug delivery market is expected to experience considerable growth through 2031, increasing from US$ 48.89 billion in 2024 to US$ 84.08 billion by 2031 at a CAGR of 8.2% during 2025–2031. Rising chronic disease prevalence, increasing demand for biologics and monoclonal antibodies, and advancements in self-injection technologies are among the major factors supporting this expansion.

North America's leading market position and Asia Pacific's projected growth opportunities highlight the importance of regional developments. Meanwhile, wearable injectors, long-acting formulations, and advanced drug administration technologies are creating new opportunities for industry participants.

Trending Reports:

·         Ambulance Equipment Market Size, Opportunities, Competitive Analysis till 2031

·         Hospital Robots Market Size, Share & Growth by 2034

·         Hospital Ward Screen Market Demand, Trends & Forecast by 2034

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturinng and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

Contact Us:

Contact Person: Ankit Mathur 
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in: Korean|German|Japanese|French|Chinese|Italian|Spanish